Business Context and Reporting Period
Nyxoah SA, a Belgian medical-device company and foreign private issuer, furnished this Form 6-K for January 2023. The filing reports a board appointment announced on January 9, 2023, following the board’s action on January 8, 2023.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Changes
- The board appointed Wildman Ventures, LLC, represented by Daniel Wildman, as a director effective immediately.
- The appointment is subject to confirmation by the company’s shareholders at the next shareholders’ meeting.
- Wildman Ventures, LLC was also appointed to the Audit Committee and the Remuneration Committee.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operational outlook. The principal governance contingency is shareholder confirmation of the board appointment. The filing states that the information regarding the appointment is incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, subject to subsequent filings.
The company also furnished a January 9, 2023 press release as Exhibit 99.1. The press release is designated as furnished rather than filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference except where expressly stated.
Investor Verification Items
- Verify shareholder confirmation of Wildman Ventures, LLC at the next shareholders’ meeting.
- Review the composition and responsibilities of the Audit Committee and Remuneration Committee following the appointment.
- Review subsequent filings for any changes to the appointment or committee assignments.
- Consult the company’s next financial filing for financial performance, liquidity, debt, and guidance information, which are not included here.